Current Immunotherapy Approaches in Non-Hodgkin Lymphomas
Non-Hodgkin lymphomas (NHLs) are lymphoid malignancies of B- or T-cell origin. Despite great advances in treatment options and significant improvement of survival parameters, a large part of NHL patients either present with a chemotherapy-refractory disease or experience lymphoma relapse. Chemothera...
Main Authors: | Robert Pytlik, Kamila Polgarova, Jana Karolova, Pavel Klener |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-11-01
|
Series: | Vaccines |
Subjects: | |
Online Access: | https://www.mdpi.com/2076-393X/8/4/708 |
Similar Items
-
The Role of Bispecific Antibodies in Non-Hodgkin’s Lymphoma: From Structure to Prospective Clinical Use
by: Rita Tavarozzi, et al.
Published: (2022-02-01) -
Emerging Trends in Immunotherapy for Cancer
by: Alok K. Mishra, et al.
Published: (2022-09-01) -
Emerging technology trends in regulatory approvals of cancer immunotherapy drugs by the FDA and EMA
by: Maryam Monajati, et al.
Published: (2024-09-01) -
The evolving role of checkpoint inhibitors in the treatment of Hodgkin lymphoma
by: Amanda F. Cashen
Published: (2024-10-01) -
Immune checkpoint inhibitors in advanced and relapsed/refractory Hodgkin lymphoma: current applications and future prospects
by: Charles J. Milrod, et al.
Published: (2024-04-01)